Event Overview
Last year's summit attracted over 100 investors from around the world to hear about the 40 selected Australian biotechnology companies, achieving its goal of showcasing Australia's world-class R&D, late-stage and emerging companies.
One of AusBiotech’s priorities is to stimulate and support investment in Australia’s biotechnology innovation. One of the most effective ways to achieve this is to develop and manage independent investor meetings that ensure access for the Australian industry to global life science investors, a task even more important in these times of economic duress.
The presenting companies will be a mix of listed companies in late-stage development, private companies with identified product/opportunities and early-stage commercialisation companies from research institutes and universities.
""...it was really quite impressive to see how many large successful biotech companies there really are here in Australia with market caps that rival some of the biggest biotechs in the US and internationally. I think that was a great way to kick off the conference in showcasing credibility of the Australian biotech sector." - David Collier, Managing Director, CMEA Capital (San Francisco, USA
"I thought the format was a very good idea having brief, focussed presentations; it really gave the...broader perspective of what's going on in a short amount of time - I thought it was really good." - Glen Begley, Vice President and Global Head, Hematology and Oncology Research, Amgen (Thousand Oaks, USA)
By invitation only. If you would like to present (public and private companies) or attend (investors), please contact Glenn Cross at AusBiotech with expressions of interest.
E: gcross@ausbiotech.org P: +61 3 9828 1400 F: +61 3 824 5188
* Please note that all presenting companies must be current financial AusBiotech Corporate Members.
INVESTORS
International Investors
Akalpa, Life Science Consulting Limited
Amgen
Auckland UniServices Ltd
Australia Zhejiang International Business Association (AZIBA)
Biotechnology Value Fund
Blueprint Life Science Group
CMEA Capital
Cowen Healthcare Royalty Partners
Duchess Capital LLC
Eli Lilly
Genentech Inc
Hamilton BioVentures
HeathCare Ventures
Innovara
La Jolla Cove
Merck Inc
London Stock Exchange
MedImmune Ventures
Monterry Investment Management
Newstar Ventures
New Zealand Venture Investment Fund
Nextech Invest Ltd
Novo Nordisk A/S
Novozymes Biopharma AU Ltd
Otago Innovation Ltd
Paul Capital Healthcare International
Penn Pharma
Platinum Investment Management Limited
QRxPharma
RA Capital
Ranbaxy Labs
Springtree Global Investors, LLC
Sustainable Chemistry Alliance - Bioindustrial Innovation Centre
Tavistock Life Sciences
Temple Assset Management
TVM Capital GmbH
Australian Investors
AFG Venture Group
ANU Connect Ventures Pty Ltd
Aoris Nova Pty Ltd / BioFusion Capital Pty Ltd
Aragon Capital
Astellas Pharma Inc
Athenaeum Capital
Australian Ethical Investment Ltd
Australian Private Equity & Venture Capital Association Limited
BioAngels
BioPacificVentures
CK Life Sciences International Inc
CM Capital Investments
Commercialisation Australia
Dephoron Group
E.L. & C. Baillieu Stockbroking Ltd
Fairview Equity Partners
Fighting Fish Ventures
Fortbridge
Fortrend Securities
Four Hats Capital
Garvan Institute
GBS Venture Partners
GlaxoSmithKline Australia
Gold Coast Innovation Centre (GCIC)
Hirst Shabian & Hirst Advisory and Investment Services
Hunters Founders Forum
IB Australian Bioscience Fund
Ideas Connect
Invest in Australia
Janssen (Johnson & Johnson)
Kinetic Investment Partners
Logan City Council
Maia Partners
Medigen
Melbourne Angels
Merck, Sharp & Dohme
OneVentures
Pacific Channel Limited
Palmer Corporation
Paterson Securities Limited
Pfizer Australia
Queensland BioCapital Funds
RBS Morgans
Scientia Captial
SLM Corporate
Streamwise Pty Limited
Taylor Collison Ltd
Titan BioVentures Management
TM Ventures
Trans Tasman Fund Management
UniQuest Pty Ltd
Uniseed
V2V - BioFrontier Partners
Venture Capital Funds AusIndustry
Visium Capital
Waterfall Captial
Yuuwa Capital LP
